265 related articles for article (PubMed ID: 34538541)
41. Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis.
Donaldson SH; Corcoran TE; Pilewski JM; Mogayzel P; Laube BL; Boitet ER; Harris ES; Ceppe A; Edwards LJ; Zeman K; Wu J; Esther CR; Nichols DP; Bennett WD; Rowe SM
J Cyst Fibros; 2024 Jan; 23(1):155-160. PubMed ID: 37845149
[TBL] [Abstract][Full Text] [Related]
42. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two
Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849
[No Abstract] [Full Text] [Related]
43. Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
Edmondson C; Course CW; Doull I
Arch Dis Child; 2021 Oct; 106(10):941-945. PubMed ID: 33785533
[TBL] [Abstract][Full Text] [Related]
44. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
[TBL] [Abstract][Full Text] [Related]
45. New Drug Hailed as Major Breakthrough in Cystic Fibrosis.
Am J Med Genet A; 2020 Jan; 182(1):8-9. PubMed ID: 31825178
[No Abstract] [Full Text] [Related]
46. Elexacaftor/tezacaftor/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24-week observational study.
Salvatore D; Cimino G; Troiani P; Bignamini E; Esposito I; Leonetti G; Zanda M; Manunza D; Pepe A
Pediatr Pulmonol; 2022 Sep; 57(9):2253-2256. PubMed ID: 35577767
[No Abstract] [Full Text] [Related]
47. Challenges in the treatment of cystic fibrosis in the era of CFTR modulatorsAuthors' replyUse of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele a systematic review and meta-analysisDiscontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY) results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsAssessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.
Schmidt CJ; Moura LS; Dalcin PTR; Ziegler B
J Bras Pneumol; 2024 May; 50(2):e20240107. PubMed ID: 38808835
[No Abstract] [Full Text] [Related]
48. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
Rowe SM; Daines C; Ringshausen FC; Kerem E; Wilson J; Tullis E; Nair N; Simard C; Han L; Ingenito EP; McKee C; Lekstrom-Himes J; Davies JC
N Engl J Med; 2017 Nov; 377(21):2024-2035. PubMed ID: 29099333
[TBL] [Abstract][Full Text] [Related]
49. Persistence and evolution of
Armbruster CR; Hilliam YK; Zemke AC; Atteih S; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Lee SE; Cooper VS; Bomberger JM
mBio; 2024 May; 15(5):e0051924. PubMed ID: 38564694
[TBL] [Abstract][Full Text] [Related]
50. Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.
Ramos KJ; Guimbellot JS; Valapour M; Bartlett LE; Wai TH; Goss CH; Pilewski JM; Faro A; Diamond JM;
J Cyst Fibros; 2022 Sep; 21(5):745-752. PubMed ID: 35474016
[TBL] [Abstract][Full Text] [Related]
51. Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis.
DiMango E; Overdevest J; Keating C; Francis SF; Dansky D; Gudis D
J Cyst Fibros; 2021 May; 20(3):460-463. PubMed ID: 32694034
[TBL] [Abstract][Full Text] [Related]
52. Year in review 2023 - Back to the future.
Cristiani L; Fernandes FF
J Cyst Fibros; 2024 Mar; 23(2):203-207. PubMed ID: 38431442
[TBL] [Abstract][Full Text] [Related]
53. Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on
Huang Y; Paul G; Lee J; Yarlagadda S; McCoy K; Naren AP
Am J Respir Crit Care Med; 2021 Nov; 204(10):1231-1235. PubMed ID: 34379998
[No Abstract] [Full Text] [Related]
54. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
[TBL] [Abstract][Full Text] [Related]
55. Predicting weight gain in patients with cystic fibrosis on triple combination modulator.
Stewart KL; Szczesniak R; Liou TG
Pediatr Pulmonol; 2024 Jun; 59(6):1724-1730. PubMed ID: 38607242
[TBL] [Abstract][Full Text] [Related]
56. Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.
Middleton PG; Taylor-Cousar JL
Expert Rev Respir Med; 2021 Jun; 15(6):723-735. PubMed ID: 33249928
[No Abstract] [Full Text] [Related]
57. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment.
Shaughnessy CA; Zeitlin PL; Bratcher PE
Sci Rep; 2021 Oct; 11(1):19810. PubMed ID: 34615919
[TBL] [Abstract][Full Text] [Related]
58. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
59. Elexacaftor/Tezacaftor/Ivacaftor as a Bridge to Lung Retransplant in a Recipient With Cystic Fibrosis.
FitzMaurice TS; Nazareth D; Iyer K; Walshaw M; Al-Aloul M
Exp Clin Transplant; 2022 Apr; 20(4):433-435. PubMed ID: 35297329
[TBL] [Abstract][Full Text] [Related]
60. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
Taylor-Cousar JL; Munck A; McKone EF; van der Ent CK; Moeller A; Simard C; Wang LT; Ingenito EP; McKee C; Lu Y; Lekstrom-Himes J; Elborn JS
N Engl J Med; 2017 Nov; 377(21):2013-2023. PubMed ID: 29099344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
